LY3039478

DRUG6 trials

Sponsors

Eli Lilly and Company

Conditions

Advanced Solid TumorBreast CancerCholangiocarcinomaColon CancerHealthyLymphomaNeoplasm MetastasisNeoplasms

Phase 1

A Study of LY3039478 in Participants With Advanced Cancer

CompletedNCT01695005

Eli Lilly and CompanyLymphoma, Neoplasm Metastasis, Neoplasms

Start: 2012-10-31End: 2018-06-26Updated: 2025-12-26

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

CompletedNCT02518113

Eli Lilly and CompanyT-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma

Start: 2015-10-01End: 2018-01-15Updated: 2019-09-11

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

TerminatedNCT02784795

Eli Lilly and CompanyBreast Cancer, Cholangiocarcinoma, Colon Cancer +2

Start: 2016-11-04End: 2020-02-13Updated: 2025-08-21

A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors

CompletedNCT02836600

Eli Lilly and CompanyAdvanced Solid Tumor

Start: 2016-09-09End: 2023-05-30Updated: 2025-08-07

Study of LY3039478 in Healthy Participants

CompletedNCT02906618

Eli Lilly and CompanyHealthy

Start: 2016-10-04End: 2016-11-11Updated: 2025-07-09

A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants

CompletedNCT02917733

Eli Lilly and CompanyHealthy

Start: 2016-09-30End: 2016-11-30Updated: 2025-07-28

Related Papers

Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia

Therapeutic Advances in Drug Safety2025-07-312 citations

A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.

2022-08-2811 citations

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.

2021-03-0828 citations

A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors.

2020-09-1623 citations

Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer.

2020-09-1112 citations

Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution.

2019-08-08133 citations

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

Annals of Oncology2018-07-27159 citations

Abstract B083: Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in patients with advanced cancer and healthy volunteers

Molecular Cancer Therapeutics2018-01-01

Notch pathway inhibition with LY3039478 in adenoid cystic carcinoma (ACC).

Journal of Clinical Oncology2017-05-2010 citations

First-in-human study of LY3039478, a Notch signaling inhibitor in advanced or metastatic cancer.

Journal of Clinical Oncology2015-05-204 citations